Dr. Abdelhadi Rebbaa
Gennady Stolyarov II
Art Ramon Garcia, Jr.
David Wood
Ben Ballweg

On Sunday, July 28, 2024, the U.S. Transhumanist Party invited Dr. Abdelhadi Rebbaa to discuss his views regarding the potential and limitations for using senolytics to treat aging and go over alternative/complementary approaches to delay senescence onset.

Dr. Abdelhadi Rebbaa received his PhD in Biochemistry from the Université Claude Bernard, Lyon, France. He held research and faculty positions at Northwestern University, the University of Pittsburgh, and Columbia University. Over the course of his career, his research encompassed target and drug discovery and development in the fields of cancer, stem cells, and aging. He served as a Principal Investigator on multiple grants, published over 40 manuscripts, and reviewed manuscripts for several high-impact scientific journals. In his role at Ichor Therapeutics from 2018 to 2021, he oversaw the discovery and preclinical testing of small-molecule senolytics and biomarkers of aging. He then worked for SENS Research Foundation between January 2022 and January 2024, where his role was to conceive, design, and oversee research projects on senescence prevention, senolytics, and partial reprogramming. Now he works as a Project Management Consultant in New Jersey.

***

Timestamps

7:25 – Dr. Abdelhadi Rebbaa’s presentation
58:28 – External versus internal/inherent (e.g. age-related) causes of senescent cells
1:01:51 – Senomorphics versus senolytics
1:03:05 – The need to replace senescent cells that have been destroyed
1:04:03 – Whether senescent cells crowd out potentially worse cells
1:04:56 – When reprogramming helps, and when it does not
1:06:06 – Whether donating blood can reduce senescence
1:07:14 – Pros and cons of academia, for-profit, and non-profit sectors
1:08:41 – Whether senescent cells are worse than the holes where the senescent cells were (if the senescent cells cannot be replaced)
1:10:40 – How close we are to senolytics approved for use
1:11:56 – How it is good to donate blood
1:12:50 – Any non-prescription senolytics available
1:14:32 – Revisiting SA-beta-Gal
1:18:10 – Whether a young blood transfusion is comparable to a blood donation (as far as reducing negative blood components)
1:18:59 – Lifespan.io’s Rejuvenation Roadmap
1:20:21 – The relation of mental stress to senescent-cell accumulation
1:23:00 – Balancing the effects of senolytics
1:25:12 – Potentially less toxic alternatives to galactose-conjugated navitoclax
1:28:25 – Potential direction of research into senescence in the next 5-10 years
1:30:42 – Whether the Hallmarks of Aging will change
1:31:51 – How therapies for aging can best be employed
1:33:31 – Potentially the best way to treat senescent cells
1:35:10 – How the application of senescent-cell treatment is challenging because of the variety of lifespans of our various cells
1:36:58 – Where the best senolytics research is happening
1:40:22 – Whether senolytic therapies stop being beneficial for a person at a certain age
1:42:06 – Whether the loss of the ability of the body to remove senescent cells is indicative of a deeper problem
1:43:48 – What we can gain from knowing how mice respond to senolytic therapies
1:47:14 – Just how complex senescent cells and senescence can be
1:49:38 – How rejuvenating senescent cells could be better than destroying them
1:50:30 – Dr. Rebbaa’s closing remarks

***

See Dr. Abdelhadi Rebbaa’s LinkedIn profile: https://www.linkedin.com/in/abdelhadi-rebbaa-32bb9279/

Join the U.S. Transhumanist Party for free, no matter where you reside: https://transhumanist-party.org/membership/